Precipio Expands Bloodhound™ MPN Panel by Adding CALR Mutation Subtyping

Rhea-AI Summary

Precipio, Inc. (NASDAQ: PRPO) has launched an enhanced version of its Bloodhound MPN (Myeloproliferative Neoplasm) panel that can now differentiate between CALR type 1 and type 2 mutations. This advancement aligns with the latest National Comprehensive Cancer Network (NCCN) guidelines released in August 2024. The new panel is the only quantitative PCR-based panel on the market that distinguishes between CALR types alongside other relevant genes for MPN evaluation.

The inclusion of CALR mutation subtyping is significant for MPN patient care, as it can influence treatment strategies and outcomes. CALR gene mutations are prevalent in various myeloproliferative neoplasms and play a critical role in disease prognosis and therapeutic decision-making. The distinction between CALR types can indicate disease progression severity and inform physicians on specific treatment needs.

Positive

• Launch of enhanced Bloodhound MPN panel with CALR type 1 and 2 mutation differentiation
• Alignment with latest NCCN guidelines (August 2024)
• Only quantitative PCR-based panel on the market with CALR subtyping capability
• Potential for improved treatment strategies and patient outcomes in MPN care

Negative

• None.

Insights

Medical Research Analyst

The expansion of Precipio's Bloodhound™ MPN Panel to include CALR mutation subtyping is a significant development in the field of cancer diagnostics. This advancement aligns with the latest NCCN guidelines and addresses a critical need in MPN patient care. The ability to distinguish between CALR type 1 and type 2 mutations provides clinicians with more precise information for prognosis and treatment decisions.

Key points to consider:

• Precipio is now offering the only quantitative PCR-based panel that differentiates CALR subtypes alongside other relevant MPN genes.
• This enhancement can potentially improve patient outcomes by enabling more targeted therapies, especially for patients with dual mutations.
• The update demonstrates Precipio's commitment to staying at the forefront of diagnostic technology, which could strengthen its market position.

While this advancement is promising, investors should note that the impact on Precipio's financials may take time to materialize as adoption of the new panel grows. The company's ability to market this unique offering effectively will be important for translating this innovation into revenue growth.

The unique assay enables laboratories to provide clinicians with more informed treatment decisions for their patients

NEW HAVEN, Conn., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces the launch of a new version of its Bloodhound MPN (Myeloproliferative Neoplasm) panel that is now able to distinguish between CALR type 1 and type 2 mutations. The CALR mutation data plays a critical role in disease prognosis and therapeutic decision-making. This differentiation aligns with the latest National Comprehensive Cancer Network (NCCN) guidelines released in August of this year (Version 2.2024—August 8, 2024).

This is the only quantitative PCR-based panel of its kind on the market that distinguishes between CALR Type 1 and Type 2 alongside the other genes relevant to the molecular evaluation of MPN.

“As science and discovery constantly evolve the diagnostic world, Precipio is committed to maintaining its competitive advantage and being at the forefront of our industry,” said Ilan Danieli, Precipio CEO. “Our customers and their patients will continue to benefit from access to cutting-edge technologies combined with the highest clinical value, enhancing patient care.”

Clinical Significance of CALR Subtyping in MPN Management
The inclusion of CALR mutation subtyping is a direct response to the evolving landscape of MPN patient care where understanding the specific type of CALR mutation can influence treatment strategies and outcomes.

The CALR gene mutation is prevalent in various myeloproliferative neoplasms and plays a critical role in disease prognosis and therapeutic decision-making. The distinction between CALR type 1 and type 2 can indicate the severity of disease progression (prognosis) and inform the physician on the specific treatment needed to suit the patient’s situation. Furthermore, for patients with dual mutations (e.g. JAK2 & CALR), the identification of the subtype CALR mutation present can impact the selection of targeted therapies.

With the recent updates from the NCCN, healthcare providers are looking for more detailed information regarding CALR mutations, allowing them to better manage MPN patient care. Precipio’s new Bloodhound MPN assay provides them with exactly what they need to help specify an MPN subtype and to determine which CALR-positive patients may respond to CALR-targeted therapies.

Please click here for more information about Precipio’s Bloodhound MPN panel and the new CALR subtyping capabilities or contact us at contact@precipiodx.com.

About Precipio

Precipio is a healthcare biotechnology company focused on cancer diagnostics. Our mission is to address the pervasive problem of cancer misdiagnoses by developing solutions in the form of diagnostic products and services. Our products and services deliver higher accuracy, improved laboratory workflow, and ultimately better patient outcomes, which reduce healthcare expenses. Precipio develops innovative technologies in our laboratory where we design, test, validate, and use these products clinically, improving diagnostic outcomes. Precipio then commercializes these technologies as proprietary products that serve the global laboratory community and further scales Precipio’s reach to eradicate misdiagnosis. For more information, please visit www.precipiodx.com.

Please follow us on LinkedIn, Twitter @PrecipioDx and on Facebook.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the targets set herein and related timing.

Except for historical information, statements about future volumes, sales, growth, costs, cost savings, margins, earnings, earnings per share, diluted earnings per share, cash flows, plans, objectives, expectations, growth or profitability are forward-looking statements based on management’s estimates, beliefs, assumptions and projections. Words such as “could,” “may,” “expects,” “anticipates,” “will,” “targets,” “goals,” “projects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “predicts,” and variations on such words, and similar expressions that reflect our current views with respect to future events and operational, economic and financial performance, are intended to identify such forward-looking statements. These forward-looking statements are only predictions based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and our other reports filed with the U.S. Securities and Exchange Commission. Any such forward-looking statements represent management’s estimates as of the date of this press release only. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

FAQ

What new feature has Precipio (PRPO) added to its Bloodhound MPN panel?

Precipio has added the ability to distinguish between CALR type 1 and type 2 mutations in its Bloodhound MPN panel.

How does the new CALR subtyping in Precipio's (PRPO) panel align with industry standards?

The new CALR subtyping aligns with the latest National Comprehensive Cancer Network (NCCN) guidelines released in August 2024.

What is the clinical significance of CALR subtyping in Precipio's (PRPO) MPN panel?

CALR subtyping can influence treatment strategies, indicate disease progression severity, and inform specific treatment needs for MPN patients.

How does Precipio's (PRPO) new Bloodhound MPN panel compare to other products on the market?

It is the only quantitative PCR-based panel on the market that distinguishes between CALR Type 1 and Type 2 alongside other genes relevant to MPN evaluation.